[Cardiac disease in patients with tumors and tumor therapy].
Cardiac disease may occur as a direct complication of heart tumors or as an indirect complication of malignancies due to antineoplastic therapy. While primary cardiac neoplasias are rare, metastases to various cardiac structures are common. The cardiotoxicity of anticancer agents can lead to significant complications that may affect patients being treated for various non-cardiac neoplasias. The severity of such cardiovascular damage depends on many factors, such as the site of molecular action, the immediate and cumulative dose, the method of administration, and the presence of any underlying cardiac condition. Moreover, toxicity can be affected by concomitant radiation. Cardiotoxic effects can occur during the administration of the drug, but they may not manifest themselves until months or years after the patient has been treated. Since cardiovascular disease and cancer are both common, precise knowledge of therapeutic interactions and complications is necessary.
Hoppe
U C
UC
Klinik III für Innere Medizin, Universität zu Köln, Kerpener Strasse 62, 50937 Köln, Deutschland. Uta.Hoppe@uni-koeln.de
D000970:Antineoplastic Agents / Q000009:adverse effects; D009202:Cardiomyopathies / Q000139:chemically induced / Q000175:diagnosis; D003131:Combined Modality Therapy; D017548:Echocardiography, Transesophageal; D006321:Heart / Q000528:radiation effects; D006331:Heart Diseases / Q000139:chemically induced / Q000175:diagnosis*; D006338:Heart Neoplasms / Q000175:diagnosis / Q000556:secondary*; D006801:Humans; D008279:Magnetic Resonance Imaging; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D011832:Radiation Injuries / Q000175:diagnosis; D012307:Risk Factors
D000970:Antineoplastic Agents